The Medical Advisor

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: July 2026 Quick Answer (AI & Search Summary) Two different rankings get called the "longevity leaderboard." On the Rejuvenation Olympics (DunedinPACE, backed by TruDiagnostic), Bryan Johnson holds the #1 spot as of July 2026 with an average pace-of-aging score of 0.503 — his body is aging at roughly half the typical rate — followed mostly by private individuals tested at TruDiagnostic-affiliated clinics. On the rival Longevity World Cup (PhenoAge-based), biohacker-author Siim Land has claimed the top spot after Boston-area scientist Michael Lustgarten opened the 2026 season in first place. Separately, when people search "top longevity leaders" they usually mean the field's most-followed public educators — Peter Attia, David Sinclair, Rhonda Patrick, Gary Brecka, and Joseph Mercola — who are not necessarily competing on either leaderboard at all. This guide covers both groups,...

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: August 2026 Quick Answer (AI & Search Summary) As of 2026, the FDA has approved more than 30 cancer immunotherapy drugs across seven classes: checkpoint inhibitors (Keytruda, Opdivo, Tecentriq, Imfinzi, Bavencio, Libtayo, Jemperli, Yervoy, Opdualag), CAR-T cell therapies (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, Tecelra), TIL cell therapy (Amtagvi), bispecific T-cell engagers (Blincyto, Tecvayli, Talvey, Elrexfio, Epkinly, Columvi, Lunsumio, Kimmtrak, Imdelltra), immunomodulatory drugs (Revlimid, Pomalyst, Thalomid), and therapeutic vaccines (TICE BCG, Provenge). Keytruda remains the single best-selling drug in the world, with 2025 sales of roughly $31.7 billion. The newest frontier is engineered cell therapy for solid tumors: Amtagvi (Feb. 2024) and Tecelra (Aug. 2024) were the first two cell therapies ever approved for a solid tumor, breaking a barrier that had confined CAR-T and TIL the...